Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let's put Cardinal Health, Inc.CAH stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock's current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Cardinal Health has a trailing twelve months PE ratio of 8.9, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 16.1. If we focus on the long-term PE trend, Cardinal Health's current PE level puts it below its midpoint over the past five years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.
Further, the stock's PE also compares favorably with the industry's trailing twelve months PE ratio, which stands at 15.6. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should point out that Cardinal Health has a forward PE ratio (price relative to this year's earnings) of 8.9 as well, which is in line with the current level. Hence the forward earnings estimates are already incorporated in the company's current share price.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock's price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Cardinal Health has a P/S ratio of about 0.1. This is significantly lower than the S&P 500 average, which comes in at 2.9 right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, CAH is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading-at least compared to historical norms.
Broad Value Outlook
In aggregate, Cardinal Health currently has a Zacks Value Style Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Cardinal Health a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Cardinal Health is 1.4, a level that is lower than the industry average of 2.0. The PEG ratio is a modified PE ratio that takes into account the stock's earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 5.3, which is far better than the industry average of 15.6. Clearly, CAH is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Cardinal Health might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of F. This gives CAH a Zacks VGM score-or its overarching fundamental grade-of A. (You can read more about the Zacks Style Scores here >> )
Meanwhile, the company's recent earnings estimates have been disappointing. The current fiscal quarter has seen zero estimates go higher in the past sixty days compared to six lower, while the fiscal full year estimate has seen only one upward and five downward revisions in the same time period.
As a result, the current fiscal quarter consensus estimate has fallen by 16.8% in the past two months, while the fiscal full year estimate has inched lower by 0.4%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Cardinal Health, Inc. Price and Consensus
This negative trend is why the stock has just a Zacks Rank #3 (Hold) despite strong value metrics and why we are looking for in-line performance from the company in the near term.
Cardinal Health is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (among the bottom 39%) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the industry has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.